PressFebruary 3, 2023 Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
PressFebruary 3, 2023 PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
PressFebruary 3, 2023 Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
PressFebruary 3, 2023 PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
PressFebruary 3, 2023 Psyence and Eden Labs Announce Extraction and Product Development Collaboration
PressFebruary 1, 2023 PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023
PressJanuary 31, 2023 Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
PressJanuary 30, 2023 BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
PressJanuary 30, 2023 Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
PressJanuary 26, 2023 Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment
PressJanuary 25, 2023 Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
PressJanuary 25, 2023 Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
PressJanuary 20, 2023 Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
PressJanuary 20, 2023 Filament Health Announces Clinical Trial Approval in Partnership With Psychiatric Centre Copenhagen
PressJanuary 20, 2023 Mydecine Innovation Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
